SormaniMPBonzanoLRoccatagliataL. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: A meta-analytic approach. Ann Neurol2009; 65: 268–275.
2.
RíoJRoviraATintoréM. Relationship between MRI lesion activity and response to IFN-beta in relapsing–remitting multiple sclerosis patients. Mult Scler2008; 14: 479–484.
3.
LiDKPatyDW. Magnetic resonance imaging results of the PRISMS trial: A randomized, double-blind, placebo controlled study of interferon-β1a in relapsing–remitting multiple sclerosis. Ann Neurol1999; 46: 197–206.
4.
RudickRLeeJSimonJ. Defining interferon β response status in multiple sclerosis patients. Ann Neurol2004; 56: 548–555.
5.
DobsonRRudickRATurnerB. Assessing treatment response to interferon-β: Is there a role for MRI?Neurology2014; 82: 248–254.
6.
BermelRYouXFouldsP. Predictors of long-term outcome in multiple sclerosis patients treated with interferon β. Ann Neurol2013; 73: 95–103.
7.
RíoJRoviraATintoréM. Evaluating the response to glatiramer acetate in relapsing–remitting multiple sclerosis (RRMS) patients. Mult Scler2014; 20: 1602–1608.
